Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
Holding IONS?
Track your performance easily
Earnings Data
Report Date
Feb 19, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$1.11Last Year’s EPS
-$0.06Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: -8.17%
|Next Earnings Date:Feb 19, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with substantial progress in pipeline development and upcoming product launches. Despite a slight decrease in quarterly revenue and increased operating expenses, the company is well-positioned for future growth with a strong cash position and strategic investments.Company Guidance
During the Ionis Q3 2024 earnings call, the company provided guidance on several fronts. They anticipate launching their first independent product, olezarsen, targeting familial chylomicronemia syndrome (FCS) in 2024, with expectations for a blockbuster opportunity as they expand into the severe hypertriglyceridemia (sHTG) market in 2026. Ionis highlighted their upcoming potential product launches, including donidalorsen for hereditary angioedema prophylaxis, with a PDUFA date set for August 21, 2025. The company has filed for marketing approval in Europe through their commercial partner, Otsuka. Ionis also shared advancements in their pipeline, specifically focusing on their Angelman syndrome program, ION582, with plans to initiate a Phase III trial in 2025. The company reaffirmed their financial outlook, projecting 2024 revenues to exceed $575 million, and emphasized their strategic investments to sustain growth, including a recent equity offering to bolster their cash position to $2.2 billion by year-end.Olezarsen Launch Imminent
Ionis is preparing for the launch of olezarsen for familial chylomicronemia syndrome (FCS), with a significant first-mover advantage. The product is expected to launch this year, positioning Ionis to capture a lead in the triglyceride-lowering space.
Strong WAINUA Launch Performance
WAINUA product sales increased 44% in the third quarter compared to the second quarter, driven by strong demand from patients new to treatment and some switching from other treatments.
Robust Pipeline Advancements
Ionis has achieved enrollment completion in 6 Phase III studies and plans for multiple product launches and regulatory approvals in the next three years. The pipeline includes promising candidates like donidalorsen for hereditary angioedema (HAE) and ION582 for Angelman syndrome.
Financial Stability and Growth
Ionis executed an equity offering to extend its cash runway, projecting to end 2024 with $2.2 billion in cash. Revenue is on track to exceed $575 million for the year.
---
IONS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IONS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $38.80 | $39.04 | +0.62% |
| Aug 01, 2024 | $49.46 | $51.32 | +3.76% |
| May 07, 2024 | $42.28 | $40.93 | -3.19% |
| Feb 21, 2024 | $44.35 | $43.53 | -1.85% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ionis Pharmaceuticals (IONS) report earnings?
Ionis Pharmaceuticals (IONS) is schdueled to report earning on Feb 19, 2025, TBA Not Confirmed.
What is Ionis Pharmaceuticals (IONS) earnings time?
Ionis Pharmaceuticals (IONS) earnings time is at Feb 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IONS EPS forecast?
IONS EPS forecast for the fiscal quarter 2024 (Q4) is -$1.11.
---